Cidara Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$62(as of Aug 8, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Cidara Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$62
Ticker SymbolCDTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees38
CountyUSA
Market Cap$1,369.7M

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Cidara Therapeutics Inc In Our Stock Scanner

As of Aug 08, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Falling WedgeScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.